From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome

Leukemia. 2013 Aug;27(8):1757-9. doi: 10.1038/leu.2013.13. Epub 2013 Jan 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • Benzamides / metabolism*
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Biological Transport
  • Humans
  • Imatinib Mesylate
  • Intracellular Space / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Organic Cation Transporter 1 / antagonists & inhibitors
  • Organic Cation Transporter 1 / metabolism
  • Piperazines / metabolism*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / metabolism*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / metabolism*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Treatment Outcome

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Benzamides
  • Organic Cation Transporter 1
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • nilotinib